US20070072873A1 - Novel thiophene derivatives which are HM74A agonists - Google Patents

Novel thiophene derivatives which are HM74A agonists Download PDF

Info

Publication number
US20070072873A1
US20070072873A1 US11/524,145 US52414506A US2007072873A1 US 20070072873 A1 US20070072873 A1 US 20070072873A1 US 52414506 A US52414506 A US 52414506A US 2007072873 A1 US2007072873 A1 US 2007072873A1
Authority
US
United States
Prior art keywords
thiophene
carboxylic acid
acetylamino
alkyl
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/524,145
Other languages
English (en)
Inventor
Henrietta Dehmlow
Uwe Grether
Nicole Kratochwil
Robert Narquizian
Constantinos Panousis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoffmann La Roche Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to HOFFMANN-LA ROCHE INC. reassignment HOFFMANN-LA ROCHE INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: F. HOFFMANN-LA ROCHE AG
Assigned to F. HOFFMANN-LA ROCHE AG reassignment F. HOFFMANN-LA ROCHE AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DEHMLOW, HENRIETTA, GRETHER, UWE, KRATOCHWIL, NICOLE A., NARQUIZIAN, ROBERT, PANOUSIS, CONSTANTINOS
Priority to US11/638,220 priority Critical patent/US7732452B2/en
Publication of US20070072873A1 publication Critical patent/US20070072873A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

  • the invention is concerned with novel substituted thiophene derivatives of the formula (I) and pharmaceutically acceptable salts and pharmaceutically acceptable esters thereof.
  • the invention is concerned with a process for the manufacture of the above compounds, pharmaceutical preparations which contain such compounds as well as the use of these compounds for the production of pharmaceutical preparations.
  • Coronary heart disease remains the leading cause of death in Western countries. In the United States 13.2 million or 4.85% of the population is affected, with 1.2 million new or recurrent attacks and around 500 thousand deaths per year (American Heart Association, Statistics for 2001). The disease is influenced by several well-established risk factors, such as age, sex, blood lipids, blood pressure, smoking, diabetes, and body mass index (BMI) as an indicator of overweight and obesity.
  • the National Cholesterol Education Program (NCEP) Adult Treatment Panel III defines elevated plasma levels of low density lipoprotein (LDL) cholesterol (LDL-C ⁇ 160 mg/dL), and low levels of high density lipoprotein (HDL) cholesterol (HDL-C ⁇ 40 mg/dL) as independent risk factors for CHD.
  • LDL low density lipoprotein
  • HDL-C ⁇ 40 mg/dL high density lipoprotein
  • Many prospective epidemiological studies have indicated that a decreased HDL-C level is a significant independent risk factor for heart disease, while increased HDL-C levels ⁇ 60 mg/dL ( ⁇
  • Nicotinic acid (Niacin), a vitamin of the B complex, is used for almost 40 years as a lipid-lowering drug with a favorable profile for all lipoprotein classes. Numerous clinical studies have shown the beneficial effects of niacin, demonstrating a reduction of coronary artery disease and overall mortality. Niacin is the most potent agent currently available to raise HDL. It has been proposed that niacin's main mode of action is through inhibition of lipolysis in the adipose tissue having as a result the reduction of free fatty acids (FFA) in plasma and liver and consequently the decreased production of very low density lipoproteins (VLDL), accounting for the reduction of total cholesterol (TC), triglycerides (TGs), and LDL-C.
  • FFA free fatty acids
  • VLDL very low density lipoproteins
  • LPAI-HDL lipoprotein AI-HDL
  • Niacin also has anti-diabetic, anti-thrombotic and anti-inflammatory properties that contribute to the overall cardioprotective effects.
  • niacin reduces thrombosis, such as the reduction of lipoprotein (a) (Lp(a)) which is a potent inhibitor of fibrinolytic activity, and it is the only currently approved drug that effectively reduces the serum levels of Lp(a) (Carlson et al. J. Intern. Med. 1989, 226, 271-6).
  • Inflammation is a critical component of atherosclerosis, leading to recruitment of macrophages which both promote plaque development and decrease plaque stability thus increasing cardiovascular risk.
  • Niacin has been suggested to have anti-inflammatory properties, such as the reduction of C-reactive protein (CRP) levels (Grundy et al. Arch. Intern. Med. 2002, 162, 1568-76).
  • CRP C-reactive protein
  • HM74A/HM74 a G-protein coupled receptor (GPCR)
  • GPCR G-protein coupled receptor
  • a pharmaceutical composition comprising a therapeutically effective amount of a compound according to formula I or 2-methyl-4-[[(phenylmethoxy)carbonyl]amino]-3-thiophenecarboxylic acid methyl ester, and a pharmaceutically acceptable carrier and/or adjuvant.
  • a method for the treatment and/or prevention of diseases which are modulated by HM74A agonists comprising the step of administering a therapeuctically effective amount of a compound according to formula I or 2-methyl-4-[[(phenylmethoxy)carbonyl]amino]-3-thiophenecarboxylic acid methyl ester to a human being or animal in need thereof.
  • novel compounds of the present invention exceed the compounds known in the art, inasmuch as they bind to and activate HM74A.
  • the compounds of the present invention are selective for HM74A by which is meant that they show greater affinity for HM74A than for HM74.
  • the compounds of the present invention are expected to have an enhanced therapeutic potential and exhibit reduced side effects compared to nicotinic acid.
  • the compounds of the present invention can be used as medicaments for the treatment and/or prevention of diseases which are modulated by HM74A agonists.
  • diseases are increased lipid and cholesterol levels, particularly dyslipidemia, low HDL-cholesterol, atherosclerotic diseases, hypertriglyceridemia, thrombosis, angina pectoris, peripheral vascular disease, stroke, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, Alzheimer's disease, Parkinson's disease, schizophrenia, sepsis, inflammatory diseases (such as e.g. asthma, colitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as e.g. Alzheimer's disease or impaired/improvable cognitive function).
  • inflammatory diseases such as e.g. asthma, colitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as e.g. Alzheimer's disease or impaired/improvable cognitive function.
  • lower is used to mean a group consisting of one to seven, preferably of one to four carbon atom(s).
  • halogen refers to fluorine, chlorine, bromine and iodine, with fluorine, chlorine and bromine being preferred.
  • alkyl refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of one to twenty carbon atoms, preferably one to sixteen carbon atoms, more preferably one to ten carbon atoms. Alkyl groups can be substituted as described below for lower-alkyl. Lower-alkyl groups as described below also are preferred alkyl groups.
  • lower-alkyl refers to a branched or straight-chain monovalent alkyl radical of one to seven carbon atoms, preferably one to four carbon atoms. This term is further exemplified by such radicals as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, t-butyl and the like.
  • Lower-alkyl groups can optionally be substituted, e.g. by hydroxy or cyano. Such substituted lower-alkyl-groups are referred to as “hydroxy-lower-alkyl” or “cyano-lower-alkyl” respectively.
  • fluoro-lower-alkyl refers to lower-alkyl groups which are mono- or multiply substituted with fluorine.
  • fluoro-lower-alkyl groups are e.g. CFH 2 , CF 2 H, CF 3 , CF 3 CH 2 , CF 3 (CH 2 ) 2 , (CF 3 ) 2 CH and CF 2 H—CF 2 .
  • alkenyl stands for a straight-chain or branched hydrocarbon residue comprising an olefinic bond and up to 20, preferably up to 16 carbon atoms.
  • lower-alkenyl refers to a straight-chain or branched hydrocarbon residue comprising an olefinic bond and up to 7, preferably up to 4 carbon atoms, such as e.g. 2-propenyl.
  • alkinyl stands for a straight-chain or branched hydrocarbon residue comprising a triple bond and up to 20, preferably up to 16 carbon atoms.
  • lower-alkinyl refers to a straight-chain or branched hydrocarbon residue comprising a triple bond and up to 7, preferably up to 4 carbon atoms, such as e.g. 2-propinyl.
  • amino signifies a primary, secondary or tertiary amino group bonded via the nitrogen atom, with the secondary amino group carrying an alkyl or cycloalkyl substituent and the tertiary amino group carrying two similar or different alkyl or cycloalkyl substituents or the two nitrogen substitutents together forming a ring, such as, for example, —NH 2 , methylamino, ethylamino, dimethylamino, diethylamino, methyl-ethylamino, pyrrolidin-1-yl or piperidino etc., preferably primary amino, dimethylamino and diethylamino and particularly dimethylamino.
  • cycloalkyl refers to a monovalent carbocyclic radical of 3 to 10 carbon atoms, preferably 3 to 7 carbon atoms, more preferably 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • alkoxy refers to the group R′—O—, wherein R′ is an alkyl.
  • lower-alkoxy refers to the group R′—O—, wherein R′ is a lower-alkyl.
  • fluoro-lower-alkoxy refers to the group R′′—O—, wherein R′′ is fluoro-lower-alkyl.
  • fluoro-lower-alkoxy groups are e.g. CFH 2 —O, CF 2 H—O, CF 3 —O, CF 3 CH 2 —O, CF 3 (CH 2 ) 2 —O, (CF 3 ) 2 CH—O, and CF 2 H—CF 2 —O.
  • aryl alone or in combination, relates to the phenyl or naphthyl group, preferably the phenyl group, which can optionally be substituted by 1 to 5, preferably 1 to 3 substituents independently selected from the group consisting of halogen, lower-alkyl, hydroxy-lower-alkyl, lower-alkoxy, fluoro-lower-alkoxy, carboxy, carboxy-lower-alkyl, lower-alkoxy-carbonyl, lower-alkoxy-carbonyl-lower-alkyl, H 2 NC(O), (H,lower-alkyl)NC(O), (lower-alkyl) 2 NC(O), H 2 NC(O)-lower-alkyl, (H,lower-alkyl)NC(O)-lower-alkyl, (lower-alkyl) 2 NC(O)-lower-alkyl, fluoro-lower-alkyl, H 2 N-lower-alkyl, (H,
  • substituents are e.g. hydroxy, amino, NO 2 , dioxo-lower-alkylene (forming e.g. a benzodioxyl group), lower-alkylcarbonyl, lower-alkylcarbonyloxy, lower-alkylcarbonyl-NH, cycloalkyl, phenyl and phenyloxy.
  • Preferred substituents are halogen, lower-alkyl, cycloalkyl and optionally substituted phenyl.
  • aryl groups can preferably be substituted as described in the description and claims below.
  • heteroaryl refers to an aromatic 5 to 6 membered monocyclic ring or 9 to 10 membered bicyclic ring which can comprise 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulphur, such as furyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, benzoimidazolyl, indolyl, indazolyl, benzoisothiazolyl, benzoxazolyl, benzoisoxazolyl and quinolinyl.
  • a preferred heteroaryl group is pyridinyl.
  • Other preferred heteroaryl groups are pyrimidinyl and pyrazinyl.
  • a heteroaryl group may optionally have a substitution pattern as described earlier in connection with the term “aryl”.
  • heteroaryl groups can preferably be substituted as described in the description and claims below.
  • esters embraces derivatives of the compounds of formula (I), in which a carboxy group has been converted to an ester.
  • esters are preferred esters.
  • the methyl and ethyl esters are especially preferred.
  • pharmaceutically acceptable esters furthermore embraces compounds of formula (I) in which hydroxy groups have been converted to the corresponding esters with inorganic or organic acids such as, nitric acid, sulphuric acid, phosphoric acid, citric acid, formic acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulphonic acid, p-toluenesulphonic acid and the like, which are non toxic to living organisms.
  • Compounds of formula (I) in which a COOH group is present can form salts with bases.
  • Examples of such salts are alkaline, earth-alkaline and ammonium salts such as e.g. Na—, K—, Ca—, Mg— and trimethylammonium-salt.
  • the compounds of formula (I) can also be solvated, e.g. hydrated. The solvation can be effected in the course of the manufacturing process or can take place e.g. as a consequence of hygroscopic properties of an initially anhydrous compound of formula (I) (hydration).
  • the term pharmaceutically acceptable salts also includes pharmaceutically acceptable solvates.
  • the compounds of formula (I) can have one or more asymmetric C atoms and can therefore exist as an enantiomeric mixture, diastereomeric mixture or as optically pure compounds.
  • Preferred compounds of formula (I) as described above are those, wherein R 4 , R 5 , R 6 and R 7 independently from each other are hydrogen, lower-alkyl, lower-alkoxy, fluoro-lower-alkyl or fluoro-lower-alkoxy, or R 4 and R 5 are bound together to form a cycloalkyl together with the carbon atom to which they are attached and —R 4 —R 5 — is —(CH 2 ) 2-6 —, or R 6 and R 7 are bound together to form a cycloalkyl together with the carbon atom to which they are attached and —R 6 —R 7 — is —(CH 2 ) 2-6 —; and R 8 is aryl or heteroaryl, which aryl or heteroaryl is optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, lower-alkyl, hydroxy-lower-alkyl, lower-alkoxy, fluoro-lower-alkoxy,
  • X is O, —CH 2 — or NR 9 and R 9 is as above.
  • Preferred compounds of formula (I) as defined above are those, wherein X is O or —CH 2 —, preferably those, wherein X is O.
  • R 1 is hydrogen.
  • R 2 is hydrogen.
  • R 3 is hydrogen or lower-alkyl, preferably wherein R 3 is hydrogen.
  • Another preferred embodiment of the present invention relates to compounds of formula (I) as described above, wherein R 4 , R 5 , R 6 and R 7 independently from each other are hydrogen, halogen or lower-alkyl.
  • a preferred embodiment of the present invention relates to compounds of formula (I) as described above, wherein R 4 , R 5 , R 6 and R 7 independently from each other are hydrogen or lower-alkyl, preferably wherein R 4 , R 5 , R 6 and R 7 independently from each other are hydrogen or methyl.
  • m or n are larger than 1, more than one R 4 , R 5 , R 6 or R 7 occur. In such cases, the individual R 4 , R 5 , R 6 or R 7 can be equal or different.
  • the group —(CR 4 R 5 ) 3 — can e.g. be —CH(CH 3 )—CH 2 —CH 2 —.
  • m or n are larger than 1, it is preferred that only one R 4 and R 5 or R 6 and R 7 are bound together to form a cycloalkyl.
  • R 8 is aryl or heteroaryl, which aryl or heteroaryl is optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, lower-alkyl, lower-alkoxy, fluoro-lower-alkoxy, fluoro-lower-alkyl, cyano, NO 2 , cycloalkyl, pyrimidinyl, pyrazinyl, pyridinyl and phenyl, which phenyl is optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, lower-alkyl, lower-alkoxy, lower-alkyl-C(O) and lower-alkyl-C(O)N(R 10 ), and R 10 is as defined above, are preferred.
  • R 8 preferably is aryl or heteroaryl, which aryl or heteroaryl is optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, lower-alkyl, cycloalkyl and phenyl, which phenyl is optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, lower-alkyl, lower-alkoxy, lower-alkyl-C(O) and lower-alkyl-C(O)N(R 10 ).
  • R 8 is phenyl or pyridinyl, which phenyl or pyridinyl is optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, lower-alkyl, cycloalkyl and phenyl, which phenyl is optionally substituted with 1 to 3 substituents selected from the group consisting of halogen and lower-alkoxy.
  • R 8 is 4′-fluoro-biphenyl-4-yl, biphenyl-4-yl, 2′-methoxy-biphenyl-4-yl, 5-(4-fluoro-phenyl)-pyridin-2-yl, 2-Chloro-phenyl, phenyl, 3,4-dichloro-phenyl, 4-Cyclopentyl-phenyl, 4-tert-butyl-phenyl or 5-(2-fluoro-phenyl)-pyridin-2-yl.
  • R 8 is 4-pyrimidin-2-yl-phenyl, 4-pyrazin-2-yl-phenyl, 4-pyridin-2-yl-phenyl, 4-pyridin-3-yl-phenyl or biphenyl-3-yl.
  • preferred compounds are the compounds of formula (I) described in the examples as individual compounds as well as pharmaceutically acceptable salts as well as pharmaceutically acceptable esters thereof.
  • Preferred compounds of formula (I) are those selected from the group consisting of:
  • Particularly preferred compounds of formula (I) are those selected from the group consisting of
  • the compounds of general formula (I) in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.
  • the invention further relates to a process for the manufacture of compounds of formula (I) as defined above, which process comprises
  • R 12 is a carboxylic acid moiety, it is preferably pivaloylic acid, p-nitrobenzoic acid, p-trifluoromethylbenzoic acid, 2,4,6-trichloro benzoic acid, acetic acid, trifluoroacetic acid, carbonic acid monoisobutyl ester, diphenyl phosphinic acid or benzene sulfonic acid to form an asymmetric anhydride, or it is the remainder of a second moiety of formula (III) bound via an oxygen atom to form a symmetric anhydride.
  • R 12 is Cl or Br.
  • pivaloylic acid pivaloylic acid, p-nitrobenzoic acid, p-trifluoromethylbenzoic acid, 2,4,6-trichloro benzoic acid, acetic acid, trifluoroacetic acid, carbonic acid monoisobutyl ester, diphenyl phosphinic acid or benzene sulfonic acid or the remainder of a second moiety of formula (III) bound via an oxygen atom to form a symmetric anhydride, in a solvent such as dichloromethane, in the presence of a base such as triethylamine, ethyl-diisopropyl-amine, N-ethylmorpholine or DMAP (dimethyl-pyridin-4-yl-amine) at temperatures between 0° C.
  • a base such as triethylamine, ethyl-diisopropyl-amine, N-ethylmorpholine or DMAP (dimethyl-pyridin-4
  • racemic compounds (Ib) can be separated into their antipodes via diastereomeric salts by crystallization with optically pure amines such as e. g. (R) or (S)-1-phenyl-ethylamine, (R) or (S)-1-naphthalen-1-yl-ethylamine, brucine, quinine or quinidine.
  • optically pure amines such as e. g. (R) or (S)-1-phenyl-ethylamine, (R) or (S)-1-naphthalen-1-yl-ethylamine, brucine, quinine or quinidine.
  • the present invention also relates to compounds of formula (I) as defined above, when prepared by a process as described above.
  • the compounds of formula (I) can be prepared by methods known in the art or as described below in schemes 1 to 4. All starting materials are either commercially available, described in the literature or can be prepared by methods well known in the art. Unless otherwise indicated, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , X, m and n are as described above.
  • pivaloylic acid p-nitrobenzoic acid, p-trifluoromethylbenzoic acid, 2,4,6-trichloro benzoic acid, acetic acid, trifluoroacetic acid, carbonic acid monoisobutyl ester, diphenyl phosphinic acid or benzene sulfonic acid or the remainder of a second moiety of formula (III) bound via an oxygen atom to form a symmetric anhydride, are either commercially available, described in the literature or can be prepared by methods well known to a person skilled in the art. Reacting compounds of formula (III) with compounds of formula (II) results in the formation of compounds of formula (Ia) or (Ib) (step a).
  • Such amide bond formation reactions are well known in the art. E.g. if R 12 is equal to chlorine or bromine such an amide bond formation can be performed in a solvent such as dichloromethane, in the presence of a base such as triethylamine, ethyl-diisopropyl-amine or N-ethylmorpholine at temperatures between 0° C. and ambient temperature.
  • a base such as triethylamine, ethyl-diisopropyl-amine or N-ethylmorpholine at temperatures between 0° C. and ambient temperature.
  • compounds of formula (Ia) or (Ib) may be prepared by treatment of anilines (II) with carboxylic acid anhydrides (III) in a solvent such as dichloromethane, in the presence of a base such as triethylamine, ethyl-diisopropyl-amine or N-ethylmorpholine at temperatures between 0° C. and ambient temperature.
  • a base such as triethylamine, ethyl-diisopropyl-amine or N-ethylmorpholine at temperatures between 0° C. and ambient temperature.
  • condensations of amines (II) with carboxylic acids (III) can be performed using well known procedures for amide formation, such as the use of N-(3-dimethylaminopropyl)-N′-ethyl-carbodiimide-hydrochloride, HATU, TBTU or BOP (benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophoshate) in the presence of a base such as ethyl-diisopropyl-amine, triethylamine, N-methylmorpholine optionally in the presence of 4-dimethylamino-pyridine or HOBt (1-hydroxybenzo-triazole) in solvents such as dichloromethane, DMF, DMA or dioxane at temperatures between 0° C. and reflux.
  • solvents such as dichloromethane, DMF, DMA or dioxane at temperatures between 0° C. and reflux.
  • one of the starting materials (II) or (III) contains one or more functional groups which are not stable or are reactive under the conditions of the amide bond formation
  • appropriate protecting groups as described e.g. in “Protective Groups in Organic Chemistry” by T. W. Greene and P. G. M. Wutts, 2 nd Ed., 1991, Wiley N.Y.
  • Such protecting groups can be removed at a later stage of the synthesis using standard methods described in the literature.
  • racemic compounds (Ib) can be separated into their antipodes via diastereomeric salts by crystallization with optically pure amines such as e. g. (R) or (S)-1-phenyl-ethylamine, (R) or (S)-1-naphthalen-1-yl-ethylamine, brucine, quinine or quinidine.
  • optically pure amines such as e. g. (R) or (S)-1-phenyl-ethylamine, (R) or (S)-1-naphthalen-1-yl-ethylamine, brucine, quinine or quinidine.
  • ester (Ia) contains one or more functional groups which are not stable under the hydrolysis conditions
  • appropriate protecting groups as described e.g. in “Protective Groups in Organic Chemistry” by T. W. Greene and P. G. M. Wutts, 2 nd Ed., 1991, Wiley N.Y.
  • Subsequent hydrolysis and removal of the protecting group(s) provides carboxylic acid (Ib).
  • Compounds of the general formula (Ib) can contain one or more stereocenters and can optionally be separated into optically pure enantiomers or diastereomers by methods well known in the art, e. g. by HPLC chromatography, chromatography on a chiral HPLC column, chromatography with a chiral eluant or by derivatization of compound (Ib) with an optically pure alcohol to form esters, which can be separated by conventional HPLC chromatography and then converted back to the enantiomerically pure acids (Ib).
  • racemic compounds (Ib) can be separated into their antipodes via diastereomeric salts by crystallization with optically pure amines such as e. g. (R) or (S)-1-phenyl-ethylamine, (R) or (S)-1-naphthalen-1-yl-ethylamine, brucine, quinine or quinidine.
  • R 12 is equal to OH activating reagents like e. g. N-(3-dimethylaminopropyl)-N′-ethyl-carbodiimide-hydrochloride, HATU, TBTU or BOP (benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophoshate) in the presence of a base such as ethyl-diisopropyl-amine, triethylamine, N-methylmorpholine optionally in the presence of 4-dimethylamino-pyridine or HOBt (1-hydroxybenzotriazole) in solvents such as dichloromethane, DMF, DMA or dioxane at temperatures between 0° C. and ambient temperature could be used.
  • OH activating reagents like e. g. N-(3-dimethylaminopropyl)-N′-ethyl-carbodiimide-hydroch
  • DMAP dimethylaminopyridine
  • OPG refers to protected alcohols which can be made by methods well known to the person skilled in the art (as described e.g. in “Protective Groups in Organic Chemistry” by T. W. Greene and P. G. M. Wutts, 2 nd Ed., 1991, Wiley N.Y.).
  • Nucleophilic substitution reactions between compounds of formula V and compounds of formula VI to form compounds of formula Ia are well know in the art.
  • a reaction can be carried out in a polar solvent such as dimethylformamide in the presence of a base such as potassium carbonate at room temperature or at elevated temperature.
  • ethers (Ia) or (Ib) can be synthesized applying e. g. the procedure from Larock et al. (R. C. Larock et al., Organic Letters, 6, 99; 2004) using CsF in acetonitrile at ambient temperature.
  • transition metal mediated procedures for the formation of aryl ethers are reported in the literature (see e. g. J. F. Hartwig et al., J. Am. Chem. Soc., 121, 3224; 1999).
  • Mitsunobu e.g. O. Mitsunobu, Synthesis 1981, 1.
  • This transformation is preferably carried out with triphenylphosphine and di-tert-butyl-, diisopropyl- or diethyl-azodicarboxylate as reagents, in a solvent like toluene, dichloromethane or tetrahydrofuran at 0° C. to ambient temperature.
  • solvents such as acetone, acetonitrile, DMF (dimethyl formamide), DMA (dimethacetamide) or THF (tetrahydrofuran)
  • bases such as K 2 CO 3 , Cs 2 CO 3 or ethyl-diisopropylamine at temperatures ranging from ambient temperature to the reflux temperature of the solvent.
  • Such reactions are well known in the art, like e. g. Suzuki, Stille or Heck reactions (Suzuki, A. Acc. Chem. Res. 1982, 15, 178; Scott, W. J.; Crisp, G. T.; Stille, J. K. J. Am. Chem. Soc. 1984, 106, 4630; Heck, R. F. Organic React. 1982, 27, 345 respectively).
  • the counterparts of such reactions are either commercially available, described in the literature or can be prepared by methods well known to a person skilled in the art.
  • one of the starting materials (II), (IV), (V), or (VI) contains one or more functional groups which are not stable or are reactive under the conditions of the amide bond formation
  • appropriate protecting groups as described e.g. in “Protective Groups in Organic Chemistry” by T. W. Greene and P. G. M. Wutts, 2 nd Ed., 1991, Wiley N.Y.
  • Such protecting groups can be removed at a later stage of the synthesis using standard methods described in the literature.
  • Compounds of the general formula (I) can contain one or more stereocenters and can optionally be separated into optically pure enantiomers or diastereomers by methods well known in the art, e. g. by HPLC chromatography, chromatography on a chiral HPLC column, chromatography with a chiral eluant or by derivatization with an optically pure alcohol to form esters, which can be separated by conventional HPLC chromatography and then converted back to the enantiomerically pure acids (I).
  • racemic compounds can be separated into their antipodes via diastereomeric salts by crystallization with optically pure amines such as e. g. (R) or (S)-1-phenyl-ethylamine, (R) or (S)-1-naphthalen-1-yl-ethylamine, brucine, quinine or quinidine.
  • a compound of formula (I) into a pharmaceutically acceptable salt can be carried out by treatment of such a compound with physiologically compatible bases.
  • such salts are alkaline, earth-alkaline and ammonium salts such as e.g. Na—, K—, Ca— and trimethylammonium-salt.
  • a suitable solvent e.g. ethanol, ethanol-water mixture, tetrahydrofuran-water mixture
  • the conversion of compounds of formula (I) into pharmaceutically acceptable esters can be carried out e.g. by treatment of a suitable carboxy group present in the molecule with a suitable alcohol using e.g. a condensating reagent such as benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), N,N-dicylohexylcarbodiimide (DCC), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDCI) or O-(1,2-dihydro-2-oxo-1-pyridyl)-N,N,N,N-tetra-methyluronium-tetrafluorborate (TBTU).
  • a condensating reagent such as benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP),
  • the compounds of formula (I) of the present invention and 2-methyl-4-[[(phenylmethoxy)carbonyl]amino]-3-thiophenecarboxylic acid methyl ester can be used as medicaments for the treatment and/or prevention of diseases which are modulated by HM74A agonists.
  • diseases which are modulated by HM74A agonists.
  • diseases are increased lipid and cholesterol levels, particularly dyslipidemia, low HDL-cholesterol, atherosclerotic diseases, hypertriglyceridemia, thrombosis, angina pectoris, peripheral vascular disease, stroke, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, Alzheimer's disease, Parkinson's disease, schizophrenia, sepsis, inflammatory diseases (such as e.g.
  • asthma wheezing a bowel syndrome
  • colitis pancreatitis
  • diseases that have an inflammatory component such as e.g. Alzheimer's disease or impaired/improvable cognitive function.
  • the use as medicament for the treatment of atherosclerosis, low HDL cholesterol levels, non-insulin dependent diabetes mellitus, and the metabolic syndrome is preferred.
  • the invention therefore also relates to pharmaceutical compositions comprising a compound as described above or 2-methyl-4-[[(phenylmethoxy)carbonyl]amino]-3-thiophenecarboxylic acid methyl ester, and a pharmaceutically acceptable carrier and/or adjuvant.
  • the invention relates to compounds as described above or 2-methyl-4-[[(phenylmethoxy)carbonyl]amino]-3-thiophenecarboxylic acid methyl ester, for use as therapeutic active substances, especially as therapeutic active substances for the treatment and/or prevention of diseases which are modulated by HM74A agonists, particularly as therapeutically active substances for the treatment and/or prevention of increased lipid levels, increased cholesterol levels, atherosclerotic diseases, dyslipidemia, low HDL-cholesterol, hypertriglyceridemia, thrombosis, angina pectoris, peripheral vascular disease, stroke, diabetes, non-insulin dependent diabetes mellitus, metabolic syndrome, Alzheimer's disease, Parkinson's disease, schizophrenia, impaired or improvable cognitive function, sepsis, inflammatory diseases, asthma, colitis, pancreatitis and cholestasisfibrosis of the liver.
  • the invention relates to a method for the treatment and/or prevention of diseases which are modulated by HM74A agonists, particularly for the treatment and/or prevention of increased lipid levels, increased cholesterol levels, atherosclerotic diseases, dyslipidemia, low HDL-cholesterol, hypertriglyceridemia, thrombosis, angina pectoris, peripheral vascular disease, stroke, diabetes, non-insulin dependent diabetes mellitus, metabolic syndrome, Alzheimer's disease, Parkinson's disease, schizophrenia, impaired or improvable cognitive function, sepsis, inflammatory diseases, asthma, colitis, pancreatitis and cholestasisfibrosis of the liver, which method comprises administering a compound as described above or 2-methyl-4-[[(phenylmethoxy)carbonyl]amino]-3-thiophenecarboxylic acid methyl ester, to a human or animal.
  • the invention further relates to the use of compounds as defined above or 2-methyl-4-[[(phenylmethoxy)carbonyl]amino]-3-thiophenecarboxylic acid methyl ester, for the treatment and/or prevention of diseases which are modulated by HM74A agonists, particularly for the treatment and/or prevention of increased lipid levels, increased cholesterol levels, atherosclerotic diseases, dyslipidemia, low HDL-cholesterol, hypertriglyceridemia, thrombosis, angina pectoris, peripheral vascular disease, stroke, diabetes, non-insulin dependent diabetes mellitus, metabolic syndrome, Alzheimer's disease, Parkinson's disease, schizophrenia, impaired or improvable cognitive function, sepsis, inflammatory diseases, asthma, colitis, pancreatitis and cholestasisfibrosis of the liver.
  • the invention relates to the use of compounds as described above or 2-methyl-4-[[(phenylmethoxy)carbonyl]amino]-3-thiophenecarboxylic acid methyl ester, for the preparation of medicaments for the treatment and/or prevention of diseases which are modulated by HM74A agonists, particularly for the treatment and/or prevention of increased lipid levels, increased cholesterol levels, atherosclerotic diseases, dyslipidemia, low HDL-cholesterol, hypertriglyceridemia, thrombosis, angina pectoris, peripheral vascular disease, stroke, diabetes, non-insulin dependent diabetes mellitus, metabolic syndrome, Alzheimer's disease, Parkinson's disease, schizophrenia, impaired or improvable cognitive function, sepsis, inflammatory diseases, asthma, colitis, pancreatitis and cholestasisfibrosis of the liver.
  • Such medicaments comprise a compound as described above.
  • Nicotinic acid binding assays were performed with membrane preparations.
  • Binding reactions contained 20 ⁇ g membranes as determined by BCA protein assay (Pierce), 50 nM [ 3 H]-nicotinic acid (Amersham) with or without compound addition in 250 ⁇ l of binding buffer (50 mM Tris pH 7.4, 2 mM MgCl 2 , 0.02% CHAPS). Incubations were carried out at room temperature for 2 hrs and terminated by filtration using a Filtermate Harvester (PerkinElmer) onto GF/C filter plates (Millipore).
  • Tris buffer 50 mM Tris pH 7.4, containing protease inhibitors.
  • Binding reactions contained 20 ⁇ g membranes as determined by BCA protein assay (Pierce), 50 nM [ 3 H]-nicotinic acid (Amersham) with or without compound addition in 250 ⁇ l of binding buffer (50 mM Tris pH 7.4, 2 mM MgCl 2 , 0.02% CHAPS). Incubations were carried out at room temperature for 2 hrs and terminate
  • Bound [ 3 H]-nicotinic acid was determined by scintillation counting using Top Count NXT (PerkinElmer). Compounds were dissolved in a concentration of 10 ⁇ 2 or 10 ⁇ 3 M in DMSO, further dilutions were performed in binding buffer. The effects of compounds were expressed as % inhibition of [ 3 H]-nicotinic acid binding. Sigmoidal curves were fitted using the XLfit3 program (ID Business Solutions Ltd. UK) and IC 50 values determined.
  • the compounds of the present invention exhibit IC 50 values in a range of about 0.001 ⁇ M to about 100 ⁇ M in the binding assay.
  • the compounds of the present invention have IC 50 values in a range of about 0.001 ⁇ M to about 10.0 ⁇ M, more preferably about 0.001 ⁇ M to about 1 ⁇ M.
  • FLIPR Fluorescent Calcium Indicator Assay
  • HEK-293 cells were grown in tissue culture medium (DMEM/Nut mix F12 Medium with Glutamax I (Invitrogen), containing 10% FBS) at 37° C. in a 5% CO 2 atmosphere. These cells were cultured in 6-well dishes at 3 ⁇ 10 5 cells/well and double transfected with DNA vectors (pcDNA3.1, Invitrogen) expressing either HM74A or HM74 and the chimeric G protein Gqi9. Two days after transfection the wells were combined and plated in 150 cm 2 flasks, in the presence of 50 ⁇ g/ml Hygromycin (Invitrogen) and 500 ⁇ g/ml Geneticin (Gibco).
  • tissue culture medium DMEM/Nut mix F12 Medium with Glutamax I (Invitrogen)
  • FBS fetal bovine serum
  • HEK-293 cells expressing either HM74A or HM74 and the chimeric G protein Gqi9 were plated at 50,000 cells/well in black 96-well plates with clear bottom (Costar) and cultured to confluency overnight in growth media (DMEM/Nut mix F12 Medium with Glutamax I (Invitrogen), containing 10% FBS) at 37° C. in a humidified cell incubator containing 5% CO 2 .
  • the compounds of the present invention exhibit EC 50 values in a range of about 0.001 ⁇ M about 100 ⁇ M in the FLIPR assay.
  • the compounds of the present invention have EC 50 values in a range of about 0.001 ⁇ M to about 10.0 ⁇ M; more preferably about 0.001 ⁇ M to about 1 ⁇ M.
  • the compounds of formula I and/or their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical preparations for enteral, parenteral or topical administration. They can be administered, for example, perorally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions or suspensions or infusion solutions, or topically, e.g. in the form of ointments, creams or oils. Oral administration is preferred.
  • the production of the pharmaceutical preparations can be effected in a manner which will be familiar to any person skilled in the art by bringing the described compounds of formula I and/or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
  • Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials.
  • lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragées and hard gelatine capsules.
  • Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers might, however, be required in the case of soft gelatine capsules).
  • Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like.
  • Suitable carrier materials for injection solutions are, for example, water, alcohols, polyols, glycerol and vegetable oils.
  • Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols.
  • Suitable carrier materials for topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.
  • Usual stabilizers preservatives, wetting and emulsifying agents, consistency-improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.
  • the dosage of the compounds of formula I can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case.
  • the compound could be administered with one or several daily dosage units, e.g. in 1 to 3 dosage units.
  • the pharmaceutical preparations conveniently contain about 1-1000 mg, preferably 1-300 mg, more preferably 1-100 mg, of a compound of formula I.
  • Step 1 4-[2-(4-Iodo-phenoxy)-acetylamino]-thiophene-3-carboxylic acid methyl ester
  • Step 2 4-[2-(4′-Fluoro-biphenyl-4-yloxy)-acetylamino]-thiophene-3-carboxylic acid methyl ester
  • reaction mixture was then stirred for 90 min at 80° C. under argon atmosphere before allowing to cool down to room temperature and diluting with ethyl acetate.
  • the reaction mixture was then filtered; the filtrate was then washed twice with brine and dried over sodium sulfate before being concentrated in vacuo.
  • the residue was then filtered through a pad of silica (SiO 2 , EtOAc, 100%) to yield the title compound as a light brown solid (138 mg, 99%).
  • Step 3 4-[2-(4′-Fluoro-biphenyl-4-yloxy)-acetylamino]-thiophene-3-carboxylic acid
  • Step 1 4-[2-(Biphenyl-4-yloxy)-acetylamino]-thiophene-3-carboxylic acid methyl ester
  • Step 2 4-[2-(Biphenyl-4-yloxy)-acetylamino]-thiophene-3-carboxylic acid
  • step 2 From 4-[2-(4-iodo-phenoxy)-acetylamino]-thiophene-3-carboxylic acid methyl ester (example 1, step 1) and 2-methoxybenzeneboronic acid was prepared 4-[2-(2′-methoxy-biphenyl-4-yloxy)-acetylamino]-thiophene-3-carboxylic acid methyl ester.
  • step 2 From 4-[2-(4-iodo-phenoxy)-acetylamino]-thiophene-3-carboxylic acid methyl ester (example 1, step 1) and o-tolylboronic acid was prepared 4-[2-(2′-methyl-biphenyl-4-yloxy)-acetylamino]-thiophene-3-carboxylic acid methyl ester.
  • step 2 From 4 -[2-(4-iodo-phenoxy)-acetylamino]-thiophene-3-carboxylic acid methyl ester (example 1, step 1) and 3-acetamidobenzeneboronic acid was prepared 4-[2-(3′-acetylamino-biphenyl-4-yloxy)-acetylamino]-thiophene-3-carboxylic acid methyl ester.
  • step 2 In analogy to Example 1 (step 2) from 4-[2-(4-iodo-phenoxy)-acetylamino]-thiophene-3-carboxylic acid methyl ester (example 1, step 1) and 3-methoxyphenyl boronic acid was prepared 4-[2-(4-iodo-phenoxy)-acetylamino]-thiophene-3-carboxylic acid methyl ester.
  • step 2 In analogy to Example 1 (step 2) from 4-[2-(4-iodo-phenoxy)-acetylamino]-thiophene-3-carboxylic acid methyl ester (example 1, step 1) and 3-acetylbenzeneboronic acid was prepared 4-[2-(3′-acetyl-biphenyl-4-yloxy)-acetylamino]-thiophene-3-carboxylic acid methyl ester.
  • Step 1 4-(5-Phenyl-pentanoylamino)-thiophene-3-carboxylic acid methyl ester
  • Step 2 4-(5-Phenyl-pentanoylamino)-thiophene-3-carboxylic acid
  • Step 1 4-[2-(5-Bromo-pyridin-2-yloxy)-acetylamino]-thiophene-3-carboxylic acid methyl ester
  • Step 2 4- ⁇ 2-[5-(2-Methoxy-phenyl)-pyridin-2-yloxy]-acetylamino ⁇ -thiophene-3-carboxylic acid methyl ester
  • Step 3 4- ⁇ 2-[5-(2-Methoxy-phenyl)-pyridin-2-yloxy]-acetylamino ⁇ -thiophene-3-carboxylic acid
  • Example 10 In analogy to Example 2, from 4-[2-(5-bromo-pyridin-2-yloxy)-acetylamino]-thiophene-3-carboxylic acid methyl ester (example 10, step 1) and 4-fluoroboronic acid was prepared 4- ⁇ 2-[5-(4-fluoro-phenyl)-pyridin-2-yloxy]-acetylamino ⁇ -thiophene-3-carboxylic acid methyl ester.
  • Step 1 4-(2-Chloro-phenoxy)-butyric acid [5057-52-3]
  • Step 3 4-[4-(2-Chloro-phenoxy)-butyrylamino]-thiophene-3-carboxylic acid methyl ester
  • Step 4 4-[4-(2-Chloro-phenoxy)-butyrylamino]-thiophene-3-carboxylic acid
  • Step 1 4-[2-(3,4-Dichloro-phenoxy)-acetylamino]-thiophene-3-carboxylic acid methyl ester
  • Step 2 4-[2-(3,4-Dichloro-phenoxy)-acetylamino]-thiophene-3-carboxylic acid
  • Step 1 4-[2-(5-Bromo-pyridin-2-yloxy)-acetylamino]-thiophene-3-carboxylic acid methyl ester
  • Step 2 4- ⁇ 2-[5-(2-Chloro-phenyl)-pyridin-2-yloxy]-acetylamino ⁇ -thiophene-3-carboxylic acid methyl ester
  • Step 3 4- ⁇ 2-[5-(2-Chloro-phenyl)-pyridin-2-yloxy]-acetylamino ⁇ -thiophene-3-carboxylic acid
  • Step 1 4-[2-(4-Cyclohexyl-phenoxy)-acetylamino]-thiophene-3-carboxylic acid methyl ester
  • Step 2 4-[2-(4-Cyclohexyl-phenoxy)-acetylamino]-thiophene-3-carboxylic acid
  • step 2 From 2-fluorophenyl boronic acid and 4-[2-(5-bromo-pyridin-2-yloxy)-acetylamino]-thiophene-3-carboxylic acid methyl ester was prepared 4- ⁇ 2-[5-(2-fluoro-phenyl)-pyridin-2-yloxy]-acetylamino ⁇ -thiophene-3-carboxylic acid methyl ester.
  • Step 1 4-[2-(4-Pyrimidin-2-yl-phenoxy)-acetylamino]-thiophene-3-carboxylic acid methyl ester
  • Step 2 4-[2-(4-Pyrimidin-2-yl-phenoxy)-acetylamino]-thiophene-3-carboxylic acid
  • Step 1 4-(2-Chloro-2-fluoro-acetylamino)-thiophene-3-carboxylic acid methyl ester
  • Steps 2 and 3 Rac-4-[2-Fluoro-2-(4′-fluoro-biphenyl-4-yloxy)-acetylamino]-thiophene-3-carboxylic acid
  • Example 58 the title compound was prepared using 4-amino-thiophene-3-carboxylic acid methyl ester, chlorodifluoroacetyl chloride and 4-fluoro-4′-hydroxybiphenyl. MS (m/e): 406.1 (M ⁇ H)).
  • Film coated tablets containing the following ingredients can be manufactured in a conventional manner: Ingredients Per tablet Kernel: Compound of formula (I) 10.0 mg 200.0 mg Microcrystalline cellulose 23.5 mg 43.5 mg Lactose hydrous 60.0 mg 70.0 mg Povidone K30 12.5 mg 15.0 mg Sodium starch glycolate 12.5 mg 17.0 mg Magnesium stearate 1.5 mg 4.5 mg (Kernel Weight) 120.0 mg 350.0 mg Film Coat: Hydroxypropyl methyl cellulose 3.5 mg 7.0 mg Polyethylene glycol 6000 0.8 mg 1.6 mg Talc 1.3 mg 2.6 mg Iron oxide (yellow) 0.8 mg 1.6 mg Titanium dioxide 0.8 mg 1.6 mg
  • the active ingredient is sieved and mixed with microcristalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidone in water.
  • the granulate is mixed with sodium starch glycolate and magesiumstearate and compressed to yield kernels of 120 or 350 mg respectively.
  • the kernels are lacquered with an aqueous solution/suspension of the above mentioned film coat.
  • Capsules containing the following ingredients can be manufactured in a conventional manner: Ingredients Per capsule Compound of formula (I) 25.0 mg Lactose 150.0 mg Maize starch 20.0 mg Talc 5.0 mg
  • the components are sieved and mixed and filled into capsules of size 2.
  • Injection solutions can have the following composition: Compound of formula (I) 3.0 mg Polyethylene Glycol 400 150.0 mg Acetic Acid q.s. ad pH 5.0 Water for injection solutions ad 1.0 ml
  • the active ingredient is dissolved in a mixture of Polyethylene Glycol 400 and water for injection (part).
  • the pH is adjusted to 5.0 by Acetic Acid.
  • the volume is adjusted to 1.0 ml by addition of the residual amount of water.
  • the solution is filtered, filled into vials using an appropriate overage and sterilized.
  • Soft gelatin capsules containing the following ingredients can be manufactured in a conventional manner: Capsule contents Compound of formula (I) 5.0 mg Yellow wax 8.0 mg Hydrogenated Soya bean oil 8.0 mg Partially hydrogenated plant oils 34.0 mg Soya bean oil 110.0 mg Weight of capsule contents 165.0 mg Gelatin capsule Gelatin 75.0 mg Glycerol 85% 32.0 mg Karion 83 8.0 mg (dry matter) Titanium dioxide 0.4 mg Iron oxide yellow 1.1 mg
  • the active ingredient is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size.
  • the filled soft gelatin capsules are treated according to the usual procedures.
  • Sachets containing the following ingredients can be manufactured in a conventional manner: Compound of formula (I) 50.0 mg Lactose, fine powder 1015.0 mg Microcrystalline cellulose (AVICEL PH 102) 1400.0 mg Sodium carboxymethyl cellulose 14.0 mg Polyvinylpyrrolidone K 30 10.0 mg Magnesium stearate 10.0 mg Flavoring additives 1.0 mg
  • the active ingredient is mixed with lactose, microcrystalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidone in water.
  • the granulate is mixed with magnesium stearate and the flavouring additives and filled into sachets.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
US11/524,145 2005-06-27 2006-09-20 Novel thiophene derivatives which are HM74A agonists Abandoned US20070072873A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/638,220 US7732452B2 (en) 2005-06-27 2006-12-13 Thiophene derivatives which are HM74A agonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05108907.6 2005-09-27
EP05108907 2005-09-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/638,220 Continuation-In-Part US7732452B2 (en) 2005-06-27 2006-12-13 Thiophene derivatives which are HM74A agonists

Publications (1)

Publication Number Publication Date
US20070072873A1 true US20070072873A1 (en) 2007-03-29

Family

ID=37398750

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/524,145 Abandoned US20070072873A1 (en) 2005-06-27 2006-09-20 Novel thiophene derivatives which are HM74A agonists
US11/638,220 Expired - Fee Related US7732452B2 (en) 2005-06-27 2006-12-13 Thiophene derivatives which are HM74A agonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/638,220 Expired - Fee Related US7732452B2 (en) 2005-06-27 2006-12-13 Thiophene derivatives which are HM74A agonists

Country Status (10)

Country Link
US (2) US20070072873A1 (de)
EP (1) EP1931651A1 (de)
JP (1) JP2009510016A (de)
KR (1) KR101018917B1 (de)
CN (1) CN101268063B (de)
AU (1) AU2006298787B2 (de)
BR (1) BRPI0616759A2 (de)
CA (1) CA2622334C (de)
IL (1) IL189928A0 (de)
WO (1) WO2007039482A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2010512A4 (de) * 2006-04-11 2010-02-24 Merck & Co Inc Niacin-rezeptoragonisten, zusammensetzungen mit derartigen verbindungen und behandlungsverfahren
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1939181A1 (de) * 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituierte Carboxamide und deren Verwendung für die Stimulierung der NO Synthase Expression
WO2009158646A1 (en) * 2008-06-27 2009-12-30 Elixir Pharmaceuticals, Inc. Therapeutic compunds and related methods of use
CN104710403A (zh) * 2015-02-11 2015-06-17 佛山市赛维斯医药科技有限公司 一类卤代噻吩酰胺甲苯类双靶点抑制剂及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3305866A1 (de) * 1983-02-19 1984-08-23 Basf Ag, 6700 Ludwigshafen Thiophen-carbonester, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
DE19935219A1 (de) * 1999-07-27 2001-02-01 Boehringer Ingelheim Pharma Carbonsäureamide, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
ES2361011T3 (es) * 2002-05-20 2011-06-13 Bristol-Myers Squibb Company Inhibidores del virus de la hepatitis c.
JP4473698B2 (ja) * 2003-10-31 2010-06-02 武田薬品工業株式会社 ピリジン化合物
TW200523252A (en) * 2003-10-31 2005-07-16 Takeda Pharmaceutical Pyridine compounds
GB0503053D0 (en) * 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
WO2007015744A1 (en) * 2005-07-21 2007-02-08 Incyte Corporation Disubstituted thienyl compounds and their use as pharmaceuticals
AU2007238879A1 (en) * 2006-04-11 2007-10-25 Merck Sharp & Dohme Corp. Niacin receptor agonists, compositions containing such compounds and methods of treatment

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2010512A4 (de) * 2006-04-11 2010-02-24 Merck & Co Inc Niacin-rezeptoragonisten, zusammensetzungen mit derartigen verbindungen und behandlungsverfahren
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds

Also Published As

Publication number Publication date
AU2006298787B2 (en) 2010-12-16
CN101268063A (zh) 2008-09-17
CA2622334A1 (en) 2007-04-12
BRPI0616759A2 (pt) 2011-06-28
EP1931651A1 (de) 2008-06-18
CA2622334C (en) 2011-03-22
KR101018917B1 (ko) 2011-03-02
US20070161650A1 (en) 2007-07-12
JP2009510016A (ja) 2009-03-12
CN101268063B (zh) 2012-02-29
AU2006298787A1 (en) 2007-04-12
IL189928A0 (en) 2008-08-07
US7732452B2 (en) 2010-06-08
KR20080042145A (ko) 2008-05-14
WO2007039482A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
US7858645B2 (en) Indazole derivatives
US8580784B2 (en) Method for treating a disease related to the glucocorticoid receptor
MXPA06002551A (es) Compuestos de aril o heteroaril amida.
JP2013047189A (ja) 新規パラバン酸誘導体及びそれらを有効成分とする医薬
US6849635B2 (en) Sulfonamides
US20100152188A1 (en) Novel Heterocyclic Compounds
US7732452B2 (en) Thiophene derivatives which are HM74A agonists
US7989657B2 (en) Anthranilic acid derivatives
US20120316169A1 (en) 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them
US7816397B2 (en) Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes
US20150018411A1 (en) Compounds as ppar beta/delta inhibitors for treating ppar beta/delta-mediated diseases
EP1379519A1 (de) Pyrrolidinsulfonamide
CN117658868A (zh) 一种苯甲酰胺类衍生物及其制备方法和用途
US20050203172A1 (en) Novel compounds

Legal Events

Date Code Title Description
AS Assignment

Owner name: F. HOFFMANN-LA ROCHE AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DEHMLOW, HENRIETTA;GRETHER, UWE;KRATOCHWIL, NICOLE A.;AND OTHERS;REEL/FRAME:018544/0583

Effective date: 20060828

Owner name: HOFFMANN-LA ROCHE INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:F. HOFFMANN-LA ROCHE AG;REEL/FRAME:018536/0775

Effective date: 20060829

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION